The Access Foundation has awarded £5,000 to Cure Leukaemia to help fund a Clinical Trials Research Nurse at Nottingham City Hospital. This specialist role is vital in enabling life-saving blood cancer trials to run safely and effectively, giving patients access to new treatments that go beyond standard NHS care. 

Blood cancer charity Cure Leukaemia was founded in 2003 by Professor Charlie Craddock CBE and businessman Graham Silk to bring pioneering treatments to patients who would not otherwise have access to them. From its beginnings in Birmingham, the charity has grown into a national organisation, funding research nurses and clinical trials across 15 leading blood cancer centres in the UK.

Cure Leukaemia’s vision is to accelerate new treatments for patients by funding the Trials Acceleration Programme (TAP) — a network that connects 20 million people with world-class clinical trials. Without dedicated research nurses, many of these trials would not take place. Over the past two decades, Cure Leukaemia has raised millions to expand its reach, support more patients and save the NHS significant costs. 

Each research nurse monitors patients closely, supports them and their families through treatment, and enables new therapies to be tested and developed. By funding this role, the Foundation is helping to accelerate progress in blood cancer treatment and improve survival rates for thousands of people diagnosed each year. 

Looking ahead, Cure Leukaemia remains committed to sustaining and expanding its national network so that more patients, wherever they live, can access pioneering new treatments and hope for a brighter future.